166196-05-0

Basic information

• Product Name: 3-Amino-2-hydroxyhexanoic acid
• Synonyms: 3-Amino-2-hydroxyhexanoic acid
• CAS NO: 166196-05-0
• Molecular Formula: C₆H₁₃NO₃
• Molecular Weight: 147.17
• Mol File: 166196-05-0.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 337.0±27.0 °C(Predicted)
• Appearance: /
• Density: 1.185
• PKA: 3.04±0.32(Predicted)
• CAS DataBase Reference: 3-Amino-2-hydroxyhexanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Amino-2-hydroxyhexanoic acid(166196-05-0)
• EPA Substance Registry System: 3-Amino-2-hydroxyhexanoic acid(166196-05-0)

Safety Data

• Hazardous Substances Data: 166196-05-0(Hazardous Substances Data)

Usage

General Description

3-Amino-2-hydroxyhexanoic acid, also known as AHHA, is a chemical compound with the molecular formula C6H13NO3. It is an important intermediate for the synthesis of pharmaceuticals, particularly for the production of antifungal agents such as griseofulvin. AHHA is a versatile building block in organic synthesis and has a wide range of applications in the pharmaceutical industry. It is also used in the production of biodegradable polymers and as a chiral building block for the synthesis of various complex molecules. AHHA has potential therapeutic applications and is being researched for its potential as a drug candidate for various medical conditions.

Upstream product

• 367258-42-2 2-hydroxy-3-nitrohexanoic acid 

Downstream Products

• 1166397-39-2 N-cyclopropyl-3-amino-2-hydroxyhexanamide hydrochloride 
• 371111-11-4 (S)-(2-{3-[((9S,12S,15S)-15-tert-Butoxycarbonylamino-12-cyclohexyl-11,14-dioxo-2-oxa-10,13-diaza-tricyclo[15.2.2.1^3,7]docosa-1⁽²⁰⁾,3,5,7⁽²²⁾,17⁽²¹⁾,18-hexaene-9-carbonyl)-amino]-2-oxo-hexanoylamino}-acetylamino)-phenyl-acetic acid benzyl ester 
• 371111-93-2 (S)-(2-{3-[((9S,12S,15S)-15-tert-Butoxycarbonylamino-12-cyclohexyl-11,14-dioxo-2-oxa-10,13-diaza-tricyclo[15.2.2.1^3,7]docosa-1⁽²⁰⁾,3,5,7⁽²²⁾,17⁽²¹⁾,18-hexaene-9-carbonyl)-amino]-2-hydroxy-hexanoylamino}-acetylamino)-phenyl-acetic acid benzyl ester 
• 371110-93-9 (S)-(2-{3-[((9S,12S)-12-Cyclohexyl-11,14-dioxo-2-oxa-10,13-diaza-tricyclo[17.2.2.1^3,7]tetracosa-1⁽²²⁾,3,5,7⁽²⁴⁾,19⁽²³⁾,20-hexaene-9-carbonyl)-amino]-2-oxo-hexanoylamino}-acetylamino)-phenyl-acetic acid tert-butyl ester 

Relevant articles and documents

Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors

Herein, we report the synthesis and structure-activity relationship studies of new analogs of boceprevir 1 and telaprevir 2. Introduction of azetidine and spiroazetidines as a P2 substituent that replaced the pyrrolidine moiety of 1 and 2 led to the disco

Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles

The hepatitis C virus (HCV) NS3 protease is essential for viral replication. It has been a target of choice for intensive drug discovery research. On the basis of an active pentapeptide inhibitor, 1, we envisioned that macrocyclization from the P2 proline

Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6, 6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: A potential therapeutic agent for the treatment of hepatitis C infection

Hepatitis C virus (HCV) infection is the major cause of chronic liver disease, leading to cirrhosis and hepatocellular carcinoma, which affects more than 170 million people worldwide. Currently the only therapeutic regimens are subcutaneous interferon-α or polyethylene glycol (PEG)-interferon-α alone or in combination with oral ribavirin. Although combination therapy is reasonably successful with the majority of genotypes, its efficacy against the predominant genotype (genotype 1) is moderate at best, with only about 40% of the patients showing sustained virological response. Herein, the SAR leading to the discovery of 70 (SCH 503034), a novel, potent, selective, orally bioavailable NS3 protease inhibitor that has been advanced to clinical trials in human beings for the treatment of hepatitis C viral infections is described. X-ray structure of inhibitor 70 complexed with the NS3 protease and biological data are also discussed.